The two FDA-approved aptamer drugs, Macugen (pegaptanib) and Avacincaptad Pegol (ZIMURGA), represent two distinct generations in pharmaceutical history. Macugen, approved in 2004, was the pioneer—the first aptamer to market—but ultimately lost its dominance in the Wet AMD market to more potent antibody drugs, resulting in negligible current revenue. In contrast, ZIMURGA, approved nearly two decades later in 2023, is a modern success story. Targeting Geographic Atrophy (GA) by inhibiting Complement Factor C5, ZIMURGA has leveraged the unique specificity of aptamers to secure a significant first-mover advantage in an underserved market, demonstrating rapid revenue growth and establishing a new frontier for the technology.
| Feature | Macugen (Pegaptanib Sodium) | Avacincaptad Pegol (ZIMURGA) |
| Approval Date | 2004 (First Aptamer Approved) | 2023 (Second Aptamer Approved) |
| Sponsor | OSI Pharmaceuticals / Pfizer | Iveric Bio / Astellas |
| Indication | Neovascular (Wet) Age-related Macular Degeneration (AMD) | Geographic Atrophy (GA), a severe form of dry AMD |
| Target | VEGF165 (Vascular Endothelial Growth Factor isoform 165) | Complement Factor C5 (A key protein in the immune complement cascade) |
| Mechanism of Action (MOA) | Ligand Blockade/Antagonism. Binds specifically to the VEGF165 protein, preventing it from interacting with its cellular receptors. | Complement Inhibition. Binds to Complement Factor C5, preventing its activation and subsequent downstream inflammatory and destructive effects. |
| Drug Class | RNA Aptamer | RNA Aptamer |
| Chemical Structure | Chemically synthesized RNA oligonucleotide | Chemically synthesized RNA oligonucleotide |
| Pharmacokinetic (PK) Modification | $\text{PEG}$ylation (Polyethylene Glycol) | $\text{PEG}$ylation (Polyethylene Glycol) |
| Reason for $\text{PEG}$ylation | To protect the nucleic acid backbone from nuclease degradation and delay renal clearance, ensuring a sustained half-life in the vitreous humor. | Same as Macugen; optimizes the PK profile to allow for less frequent intravitreal dosing. |
| Route of Administration | Intravitreal Injection (into the eye) | Intravitreal Injection (into the eye) |
| Manufacturing | Non-biological (Chemical Synthesis) | Non-biological (Chemical Synthesis) |
| Market Success | High efficacy, but rapidly superseded by more effective second-generation anti-VEGF antibodies (Lucentis, Eylea). | High efficacy in an unserved market, establishing long-term commercial dominance. |